Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry

被引:14
作者
Salvatore, Donatello [1 ]
Padoan, Rita [2 ]
Buzzetti, Roberto
Amato, Annalisa [3 ]
Giordani, Barbara [3 ,4 ]
Ferrari, Gianluca [3 ]
Majo, Fabio [3 ,5 ]
机构
[1] Hosp San Carlo, Cyst Fibrosis Ctr, Potenza, Italy
[2] ASST Spedali Civili, Cyst Fibrosis Unit, Brescia, Italy
[3] Italian Cyst Fibrosis Registry, Rome, Italy
[4] Italian Cyst Fibrosis League, Rome, Italy
[5] Bambino Gesu Pediat Hosp, IRCCS, Cyst Fibrosis Ctr, Rome, Italy
关键词
CFTR with residual function mutations; cystic fibrosis; epidemiology; patient registry; DISEASE;
D O I
10.1002/ppul.24215
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background CFTR mutations permitting residual function (RF) of the CFTR protein are disease-causing. These mutations are associated with a pneumopathy that is delayed in onset and is slower in progression than are more common forms of cystic fibrosis (CF), although the disease may become severe in some patients. RF mutations are among the most frequent in Italy, thus encouraging investigation of their prevalence and associated phenotypes. Methods Data from the Italian Registry were used to compare patients with at least one RF mutation with those homozygous for F508del. Results A total of 806 patients bearing at least one RF mutation were identified among 5204 registered patients (15.5%). The RF patients were older than the F508del homozygotes (median age 26.0 years vs 19.8 years, respectively), with a higher median age at diagnosis (6.3 years vs 0.2 years, respectively) and a lower median sweat chloride value (76.0 mmol/L vs 100.0 mmol/L, respectively). In the RF group, lung infections and comorbidities were less prevalent than those in the F508del homozygotes, while better FEV1 and nutritional status were observed at all ages. Within the RF group, RF/F508del subjects showed more severe pneumopathy than did patients with RF/other mutations. In particular, the 3849 + 10kbC -> T/F508del subjects had worse FEV1 and a higher prevalence of lung infections than did patients with other genotypes. Conclusions Patients with RF mutations are numerous in Italy and have a milder disease phenotype than do F508del homozygotes. Inside the RF group, F508del heterozygotes and, in particular, 3849 + 10kbC -> T/F508del patients showed more severe pneumopathy.
引用
收藏
页码:150 / 157
页数:8
相关论文
共 50 条
[41]   Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis [J].
Hodson, ME ;
McKenzie, S ;
Harms, HK ;
Koch, C ;
Mastella, G ;
Navarro, J ;
Strandvik, B .
PEDIATRIC PULMONOLOGY, 2003, 36 (05) :427-432
[42]   Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data [J].
Schluter, Daniela K. ;
Ostrenga, Josh S. ;
Carr, Siobhan B. ;
Fink, Aliza K. ;
Faro, Albert ;
Szczesniak, Rhonda D. ;
Keogh, Ruth H. ;
Charman, Susan C. ;
Marshall, Bruce C. ;
Goss, Christopher H. ;
Taylor-Robinson, David .
THORAX, 2022, 77 (02) :136-142
[43]   Cystic fibrosis mutations: Report from the French registry [J].
Guilloud-Bataille, M ;
De Crozes, D ;
Rault, G ;
Degioanni, A ;
Feingold, J .
HUMAN HEREDITY, 2000, 50 (02) :142-145
[44]   Clinical characteristics of patients requiring lung transplantation referral in national cystic fibrosis registry data [J].
Onay, Zeynep Reyhan ;
Eyuboglu, Tugba Sismanlar ;
Aslan, Ayse Tana ;
Gursoy, Tugba Ramasli ;
Yalcin, Ebru ;
Kiper, Nural ;
Emiralioglu, Nagehan ;
Sen, Hadice Selimoglu ;
Sen, Velat ;
Unal, Gokcen ;
Yilmaz, Asli Imran ;
Kilinc, Ayse Ayzit ;
cokugras, Haluk ;
Baskan, Azer Kilic ;
Yazan, Hakan ;
Collak, Abdulhamit ;
Uzuner, Selcuk ;
Sasihueseyinoglu, Ayse Senay ;
Ozcan, Dilek ;
Altintas, Derya Ufuk ;
Ozturk, Goekcen Kartal ;
Demir, Esen ;
Bingol, Aysen ;
Basaran, Erdem ;
Cekic, Suekrue ;
Sapan, Nihat ;
Irmak, Ilim ;
Damadoglu, Ebru ;
Tugcu, Gokcen Dilsa ;
Polat, Sanem Eryilmaz ;
Ozdemir, Ali ;
Harmanci, Koray ;
Kilic, Gonca ;
Hangul, Melih ;
Kose, Mehmet ;
Tamay, Zeynep ;
Yueksel, Hasan ;
Ozcan, Gizem ;
Topal, Erdem ;
Can, Demet ;
Korkmaz, Pervin ;
Caltepe, Gonuel ;
Kilic, Mehmet ;
Ozdogan, Sebnem ;
Cakir, Erkan ;
Cobanoglu, Nazan ;
Pekcan, Sevgi ;
Cinel, Guzin ;
Ozcelik, Ugur ;
Dogru, Deniz .
TURKISH JOURNAL OF PEDIATRICS, 2023, 65 (02) :257-268
[45]   Is deafness mutation screening required in cystic fibrosis patients? [J].
Abusamra, Rania ;
McShane, Donna .
PAEDIATRIC RESPIRATORY REVIEWS, 2016, 20 :24-26
[46]   MUTATION ANALYSIS AND HAPLOTYPE CORRELATION FOR 139 CYSTIC-FIBROSIS PATIENTS FROM THE NEBRASKA REGIONAL CYSTIC-FIBROSIS CENTER [J].
TRAYSTMAN, MD ;
SCHULTE, N ;
COLOMBO, JL ;
SAMMUT, PH ;
REILLY, P ;
PATEL, C ;
ACQUAZZINO, D ;
SIMANEK, B ;
ANDERSON, R ;
KIMBERLING, WJ ;
SCHAEFER, GB ;
SANGER, WG .
HUMAN MUTATION, 1993, 2 (01) :7-15
[47]   From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995-2006 [J].
Stern, M. ;
Wiedemann, B. ;
Wenzlaff, P. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) :29-35
[48]   Lessons from the on-site quality audit of data transmitted to the French cystic fibrosis registry [J].
Nadine Pellen ;
Laëtitia Guéganton ;
Dominique Pougheon Bertrand ;
Gilles Rault .
Orphanet Journal of Rare Diseases, 13
[49]   Lessons from the on-site quality audit of data transmitted to the French cystic fibrosis registry [J].
Pellen, Nadine ;
Gueganton, Laetitia ;
Bertrand, Dominique Pougheon ;
Rault, Gilles .
ORPHANET JOURNAL OF RARE DISEASES, 2018, 13
[50]   Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry [J].
Strobl, J ;
Enzer, I ;
Bagust, A ;
Haycox, A ;
Smyth, R ;
Ashby, D ;
Walley, T .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (06) :467-473